Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Swedberg

Showing results (391-400 of 471) with videos related to

Pageof 48
Sort By:
The American Journal of Cardiology|May 8, 2018
Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial)Muthiah Vaduganathan, Ravi B Patel, Robert J Mentz, et al.
European Journal of Heart Failure|October 2, 2008
ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)Kenneth Dickstein, Alain Cohen-Solal, Gerasimos Filippatos, et al.
JACC. Heart Failure|April 16, 2018
Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart FailureKevin Damman, Mauro Gori, Brian Claggett, et al.
European Journal of Heart Failure|November 22, 2016
Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fractionJane A Cannon, Li Shen, Pardeep S Jhund, et al.
Circulation|September 13, 2019
Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HFSenthil Selvaraj, Brian Claggett, Andrea Pozzi, et al.
European Heart Journal|July 26, 2011
Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trialJohn E A Blair, Peter S Pang, Robert W Schrier, et al.
JACC. Heart Failure|February 11, 2019
Income Inequality and Outcomes in Heart Failure: A Global Between-Country AnalysisPooja Dewan, Rasmus Rørth, Pardeep S Jhund, et al.
European Journal of Heart Failure|February 13, 2018
Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)Ulrik M Mogensen, Jianjian Gong, Pardeep S Jhund, et al.
European Journal of Heart Failure|August 19, 2003
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in contextEric J Velazquez, Marc A Pfeffer, John V McMurray, et al.
JACC. Heart Failure|June 2, 2022
Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEFJames P Curtain, Ross T Campbell, Mark C Petrie, et al.
Pageof 48

Showing results (391-400 of 471) with videos related to

Sort By:
Pageof 48
The American Journal of Cardiology|May 8, 2018
Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial)Muthiah Vaduganathan, Ravi B Patel, Robert J Mentz, et al.
European Journal of Heart Failure|October 2, 2008
ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)Kenneth Dickstein, Alain Cohen-Solal, Gerasimos Filippatos, et al.
JACC. Heart Failure|April 16, 2018
Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart FailureKevin Damman, Mauro Gori, Brian Claggett, et al.
European Journal of Heart Failure|November 22, 2016
Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fractionJane A Cannon, Li Shen, Pardeep S Jhund, et al.
Circulation|September 13, 2019
Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HFSenthil Selvaraj, Brian Claggett, Andrea Pozzi, et al.
European Heart Journal|July 26, 2011
Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trialJohn E A Blair, Peter S Pang, Robert W Schrier, et al.
JACC. Heart Failure|February 11, 2019
Income Inequality and Outcomes in Heart Failure: A Global Between-Country AnalysisPooja Dewan, Rasmus Rørth, Pardeep S Jhund, et al.
European Journal of Heart Failure|February 13, 2018
Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)Ulrik M Mogensen, Jianjian Gong, Pardeep S Jhund, et al.
European Journal of Heart Failure|August 19, 2003
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in contextEric J Velazquez, Marc A Pfeffer, John V McMurray, et al.
JACC. Heart Failure|June 2, 2022
Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEFJames P Curtain, Ross T Campbell, Mark C Petrie, et al.
Pageof 48